• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球检测与口服抗凝治疗的管理

Global assays and the management of oral anticoagulation.

作者信息

Brinkman Herm Jan M

机构信息

Department of Plasma Proteins, Sanquin Research, Plesmanlaan 125, 1066 CX Amsterdam, The Netherlands.

出版信息

Thromb J. 2015 Feb 10;13:9. doi: 10.1186/s12959-015-0037-1. eCollection 2015.

DOI:10.1186/s12959-015-0037-1
PMID:25762867
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4355453/
Abstract

Coagulation tests range from global or overall tests to assays specific to individual clotting factors and their inhibitors. Whether a particular test is influenced by an oral anticoagulant depends on the principle of the test and the type of oral anticoagulant. Knowledge on coagulation tests applicable in monitoring status and reversal of oral anticoagulation is a prerequisite when studying potential reversal agents or when managing anticoagulation in a clinical setting. Specialty tests based on the measurement of residual activated factor X (Xa) or thrombin activity, e.g., are highly effective for determining the concentration of the new generation direct factor Xa- and thrombin inhibitors, but these tests are unsuitable for the assessment of anticoagulation reversal by non-specific prohemostatic agents like prothrombin complex concentrate (PCC) and recombinant factor VIIa (FVIIa). Global coagulation assays, in this respect, seem more appropriate. This review evaluates the current status on the applicability of the global coagulation assays PT, APTT, thrombin generation and thromboelastography in the management of oral anticoagulation by vitamin K antagonists and the direct factor Xa and thrombin inhibitors. Although all global tests are influenced by both types of anticoagulants, not all tests are useful for monitoring anticoagulation and reversal thereof. Many (pre)analytical conditions are of influence on the assay readout, including the oral anticoagulant itself, the concentration of assay reagents and the presence of other elements like platelets and blood cells. Assay standardization, therefore, remains an issue of importance.

摘要

凝血检测范围从整体或全面检测到针对个别凝血因子及其抑制剂的测定。特定检测是否受口服抗凝剂影响取决于检测原理和口服抗凝剂的类型。在研究潜在的逆转剂或在临床环境中管理抗凝时,了解适用于监测口服抗凝状态和逆转的凝血检测是一个先决条件。例如,基于测量残余活化因子X(Xa)或凝血酶活性的特殊检测对于确定新一代直接因子Xa和凝血酶抑制剂的浓度非常有效,但这些检测不适用于评估非特异性促止血剂(如凝血酶原复合物浓缩物(PCC)和重组因子VIIa(FVIIa))对抗凝逆转的效果。在这方面,整体凝血检测似乎更合适。本综述评估了整体凝血检测PT、APTT、凝血酶生成和血栓弹力图在维生素K拮抗剂以及直接因子Xa和凝血酶抑制剂口服抗凝管理中的适用性现状。尽管所有整体检测都受这两种抗凝剂的影响,但并非所有检测都可用于监测抗凝及其逆转。许多(前)分析条件会影响检测读数,包括口服抗凝剂本身、检测试剂的浓度以及血小板和血细胞等其他成分的存在。因此,检测标准化仍然是一个重要问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/ba9184b097d5/12959_2015_37_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/e11987a701b8/12959_2015_37_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/30233752e53e/12959_2015_37_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/89393234e72e/12959_2015_37_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/af8d60c50fd3/12959_2015_37_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/5500e3b293de/12959_2015_37_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/96ff0c902ac0/12959_2015_37_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/faf4dad429b8/12959_2015_37_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/ba9184b097d5/12959_2015_37_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/e11987a701b8/12959_2015_37_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/30233752e53e/12959_2015_37_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/89393234e72e/12959_2015_37_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/af8d60c50fd3/12959_2015_37_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/5500e3b293de/12959_2015_37_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/96ff0c902ac0/12959_2015_37_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/faf4dad429b8/12959_2015_37_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cf6c/4355453/ba9184b097d5/12959_2015_37_Fig8_HTML.jpg

相似文献

1
Global assays and the management of oral anticoagulation.全球检测与口服抗凝治疗的管理
Thromb J. 2015 Feb 10;13:9. doi: 10.1186/s12959-015-0037-1. eCollection 2015.
2
Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.全球凝血试验:其在测量直接Xa因子和凝血酶抑制以及凝血酶原复合物浓缩物对抗凝作用的逆转方面的适用性。
Clin Chem Lab Med. 2014 Nov;52(11):1615-23. doi: 10.1515/cclm-2014-0307.
3
Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.凝血酶原复合物浓缩剂、活化凝血酶原复合物浓缩剂及重组活化因子VII在体外逆转利伐沙班诱导的抗凝作用。
Thromb Res. 2014 Apr;133(4):671-81. doi: 10.1016/j.thromres.2014.01.017. Epub 2014 Jan 21.
4
Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay.使用血栓弹力描记术和凝血酶生成试验评估利伐沙班作用的逆转。
Br J Anaesth. 2016 Nov;117(5):583-591. doi: 10.1093/bja/aew259. Epub 2016 Sep 13.
5
Coagulation Testing in the Core Laboratory.核心实验室中的凝血检测
Lab Med. 2017 Nov 8;48(4):295-313. doi: 10.1093/labmed/lmx050.
6
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.长期接受直接口服抗凝剂、凝血酶或因子 Xa 抑制剂治疗的患者的大出血并发症和紧急手术的处理:围手术期止血工作组(GIHP)的建议-2013 年 3 月。
Arch Cardiovasc Dis. 2013 Jun-Jul;106(6-7):382-93. doi: 10.1016/j.acvd.2013.04.009. Epub 2013 Jun 25.
7
Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.肝素补充剂可抵消凝血酶原复合物浓缩物和凝血因子 IX 浓缩物的促止血作用:一项体外评估。
Thromb Res. 2016 Mar;139:102-10. doi: 10.1016/j.thromres.2016.01.017. Epub 2016 Jan 25.
8
Emergency Coagulation Assessment During Treatment With Direct Oral Anticoagulants: Limitations and Solutions.直接口服抗凝剂治疗期间的紧急凝血评估:局限性与解决方案
Stroke. 2017 Sep;48(9):2457-2463. doi: 10.1161/STROKEAHA.117.017981. Epub 2017 Aug 3.
9
Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants.即时检测在直接口服抗凝剂治疗患者的紧急凝血评估中的应用。
Crit Care. 2017 Feb 15;21(1):32. doi: 10.1186/s13054-017-1619-z.
10
Management of Severe Bleeding in Patients Treated With Oral Anticoagulants: Proceedings Monograph From the Emergency Medicine Cardiac Research and Education Group-International Multidisciplinary Severe Bleeding Consensus Panel October 20, 2018.口服抗凝剂治疗患者严重出血的管理:急诊医学心脏研究与教育集团-国际多学科严重出血共识小组2018年10月20日会议纪要
Crit Pathw Cardiol. 2019 Sep;18(3):143-166. doi: 10.1097/HPC.0000000000000181.

引用本文的文献

1
Anticoagulation Monitoring with Activated Partial ThromboPlastin Time and Anti-Xa Activity in Intensive Care Unit Patients: Interest of Thrombin Generation Assay.重症监护病房患者活化部分凝血活酶时间和抗 Xa 活性的抗凝监测:凝血酶生成试验的意义。
Int J Mol Sci. 2022 Sep 23;23(19):11219. doi: 10.3390/ijms231911219.
2
In vitro reversal of direct factor Xa inhibitors: Direct comparison of andexanet alfa and prothrombin complex concentrates Cofact and Beriplex/Kcentra.直接凝血因子Xa抑制剂的体外逆转:阿哌沙班与凝血酶原复合物浓缩剂Cofact和百瑞维宁/凝血因子复合物Kcentra的直接比较
Res Pract Thromb Haemost. 2022 Aug 1;6(5):e12775. doi: 10.1002/rth2.12775. eCollection 2022 Jul.
3

本文引用的文献

1
Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.达比加群和利伐沙班对常规凝血检测的影响。一项比利时全国性调查。
Thromb Haemost. 2015 Jan;113(1):154-64. doi: 10.1160/TH14-02-0161. Epub 2014 Sep 18.
2
Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents.比较不同试剂下阿哌沙班和利伐沙班对凝血酶原和活化部分凝血活酶时间的影响。
J Thromb Haemost. 2014 Nov;12(11):1810-5. doi: 10.1111/jth.12720. Epub 2014 Oct 12.
3
Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry.
Evaluation of Biological Activity of Natural Compounds: Current Trends and Methods.
天然化合物生物活性评价:现状与方法。
Molecules. 2022 Jul 13;27(14):4490. doi: 10.3390/molecules27144490.
4
Titrated versus conventional anticoagulation management for thrombin generation in cardiac surgery: a randomized controlled trial.心脏手术中凝血酶生成的滴定与常规抗凝管理:一项随机对照试验。
Can J Anaesth. 2022 Sep;69(9):1117-1128. doi: 10.1007/s12630-022-02278-1. Epub 2022 Jul 8.
5
Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro.逆转直接凝血因子Xa或凝血酶抑制剂:在凝血酶原复合物浓缩物中添加因子V在体外是有益的。
Res Pract Thromb Haemost. 2022 Apr 25;6(3):e12699. doi: 10.1002/rth2.12699. eCollection 2022 Mar.
6
"In Less than No Time": Feasibility of Rotational Thromboelastometry to Detect Anticoagulant Drugs Activity and to Guide Reversal Therapy.“转眼间”:旋转血栓弹力图检测抗凝药物活性及指导逆转治疗的可行性
J Clin Med. 2022 Mar 4;11(5):1407. doi: 10.3390/jcm11051407.
7
The association of thrombin generation with bleeding outcomes in cardiac surgery: a prospective observational study.血栓生成与心脏手术出血结局的相关性:一项前瞻性观察研究。
Can J Anaesth. 2022 Mar;69(3):311-322. doi: 10.1007/s12630-021-02165-1. Epub 2021 Dec 22.
8
Evaluation of the Determination of Dabigatran, Rivaroxaban, and Apixaban in Lupus Anticoagulant-Positive Patients.狼疮抗凝物阳性患者中达比加群、利伐沙班和阿哌沙班测定的评估
Diagnostics (Basel). 2021 Nov 2;11(11):2027. doi: 10.3390/diagnostics11112027.
9
Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study.直接口服抗凝剂治疗患者的全球血栓弹力描记术:RO-DOA 研究。
J Thromb Thrombolysis. 2020 Feb;49(2):251-258. doi: 10.1007/s11239-019-01956-0.
10
Novel reversal agents and laboratory evaluation for direct-acting oral anticoagulants (DOAC): An update.新型直接作用口服抗凝剂(DOAC)的逆转剂及实验室评估:最新进展
Indian J Anaesth. 2019 Mar;63(3):169-181. doi: 10.4103/ija.IJA_734_18.
用旋转血栓弹性描记术测量阿哌沙班和利伐沙班的活性。
Thromb Res. 2014 Oct;134(4):918-23. doi: 10.1016/j.thromres.2014.08.006. Epub 2014 Aug 19.
4
Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.通过血栓弹力图体外监测达比加群抗凝及其逆转。
Int J Cardiol. 2014 Oct 20;176(3):794-9. doi: 10.1016/j.ijcard.2014.07.084. Epub 2014 Aug 4.
5
Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays.口服直接因子 Xa 抑制剂阿哌沙班对常规凝血检测和抗 FXa 检测的影响。
J Thromb Haemost. 2014 Sep;12(9):1545-53. doi: 10.1111/jth.12649. Epub 2014 Jul 23.
6
Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.全球凝血试验:其在测量直接Xa因子和凝血酶抑制以及凝血酶原复合物浓缩物对抗凝作用的逆转方面的适用性。
Clin Chem Lab Med. 2014 Nov;52(11):1615-23. doi: 10.1515/cclm-2014-0307.
7
Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulability in vitro and in vivo.直接凝血酶抑制剂而非直接Xa因子抑制剂利伐沙班,在体外和体内均会增加组织因子诱导的高凝性。
J Thromb Haemost. 2014 Jul;12(7):1054-65. doi: 10.1111/jth.12591. Epub 2014 Jun 19.
8
The role of prothrombin complex concentrates in reversal of target specific anticoagulants.凝血酶原复合物浓缩物在逆转靶向特异性抗凝剂中的作用。
Thromb J. 2014 Apr 17;12:8. doi: 10.1186/1477-9560-12-8. eCollection 2014.
9
Reversal of dabigatran-induced bleeding by coagulation factor concentrates in a rat-tail bleeding model and lack of effect on assays of coagulation.在大鼠尾出血模型中凝血因子浓缩物逆转达比加群引起的出血,并且对凝血检测无影响。
Anesthesiology. 2014 Jun;120(6):1429-40. doi: 10.1097/ALN.0000000000000255.
10
Indirect treatment comparison of new oral anticoagulants for the treatment of acute venous thromboembolism.新型口服抗凝剂治疗急性静脉血栓栓塞症的间接治疗比较
Thromb Res. 2014 Jun;133(6):1145-51. doi: 10.1016/j.thromres.2014.03.035. Epub 2014 Mar 24.